WHO Reports Progress in DR Congo Ebola Response

The World Health Organization stated on Wednesday that efforts to contain the Ebola outbreak in the Democratic Republic of Congo are yielding positive results, although the epidemic remains far from resolved. As of September 11, more than 7,000 confirmed cases have been reported across seven provinces, marking this as the second most lethal outbreak on record after the West African epidemic of 2014 to 2016.

According to WHO Director-General Tedros Adhanom Ghebreyesus, transmission rates are declining in the most affected areas of Ituri province. However, he cautioned that the outbreak could still spread rapidly in a region characterized by high population mobility, urging continued vigilance despite the initial improvements.

Sustained Efforts Required for Control

Maria Van Kerkhove, the WHO’s acting director for epidemic and pandemic threat management, emphasized that the situation requires long-term commitment. She noted that improved surveillance systems may lead to a higher number of detected cases, while contact-tracing efforts have been significantly expanded. "We have many, many months ahead of us," Van Kerkhove said, reinforcing the message that the crisis is ongoing.

Vaccine Trials Face Uncertainties

More than 3,000 healthcare and frontline workers have been vaccinated with Merck's Ervebo, according to Meg Doherty, the WHO's director of science and research. However, Ervebo is licensed against the Zaire ebolavirus, whereas the current outbreak is driven by the Bundibugyo strain. Doherty noted that the vaccine's effectiveness against this specific variant is not yet known.

An observational study involving frontline workers is expected to begin shortly to assess the vaccine's impact. Additionally, a separate mid-to-late-stage trial led by Congo's National Institute of Biomedical Research is set to launch in the coming weeks. Ervebo will be among the first candidates evaluated, followed by other vaccines targeting the Bundibugyo strain, including those from Moderna and the University of Oxford.

Monitoring Future Transmission Trends

As the response continues, the focus shifts to verifying whether the decline in transmission is sustainable across all affected provinces. The upcoming clinical trials will provide critical data on vaccine efficacy, which could determine the strategy for mass vaccination in the coming months. According to France 24, the international community is closely watching these developments to ensure that the hard-won gains in containment are not reversed by new transmission clusters.